MetaCap

Actinium Pharmaceuticals (Delaware) (ATNM) vs Pliant Therapeutics (PLRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Pliant Therapeutics (PLRX) over the past year, losing 21.1% versus a loss of 61.6%. Over five years, ATNM leads with a -85.6% price change compared with -95.9% for PLRX. Pliant Therapeutics is the larger company by market cap ($36.9 million vs $33.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATNM-21.05%PLRX-61.61%
+32%-17%-66%
Nov 21, 20251 yearNov 20, 2026
ATNM-86.22%PLRX-96.03%
+144%+18%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATNM versus PLRX key metrics
MetricATNMPLRX
Share price$1.05$0.5951
Market cap$33.01M$36.89M
1-day change-1.87%-4.02%
YTD return-22.79%-51.22%
1-year return-21.05%-61.61%
5-year return-85.60%-95.89%
P/E ratio (TTM)2.44—
EPS (TTM)$0.43$-1.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$90.00K$0
Net income (latest FY)$-33.89M$-149.34M
Operating margin-40274.44%—
Net margin-37652.22%—
52-week high$1.72$1.67
52-week low$0.735$0.5719
Distance from 52-week high-38.95%-64.37%
Analyst consensusnonenone
Avg. price target upside+242.86%+236.08%
Average volume193.83K408.93K
Shares outstanding31.44M61.99M
Employees2749
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATNM has outperformed PLRX by 40.6 percentage points over the past year.

About Actinium Pharmaceuticals (Delaware)

ATNM stock →

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About Pliant Therapeutics

PLRX stock →

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

ATNM vs PLRX FAQ

Which is bigger, Actinium Pharmaceuticals (Delaware) or Pliant Therapeutics?

Pliant Therapeutics (PLRX) is larger, with a market capitalization of $36.89M compared with $33.01M for Actinium Pharmaceuticals (Delaware) (ATNM).

Which stock has performed better over the past year, ATNM or PLRX?

ATNM returned -21.05% over the past 12 months, compared with -61.61% for PLRX (price return, excluding dividends). Past performance does not predict future results.

Are Actinium Pharmaceuticals (Delaware) and Pliant Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons